The US in vitro diagnostics & laboratory developed test for autoimmune disease market size was USD 5.52 Billion in 2022 and is likely to reach USD 8.35 Billion by 2031, expanding at a CAGR of 4.7 % during 2023–2031.
The market growth isattributed to increase in incidence of cancer & autoimmune diseases and advancement of technologies for diagnosis of such diseases. The US remains a highly potential market for substantial growth in the coming years owing to high investment for research and development, increasing awareness among people regarding the early diagnosis of those diseases, and availability of top class healthcare facilities.
As per the estimation by the American Autoimmune Related Diseases Association, Inc. (AARDA), nearly 50 million Americans get diagnosed with autoimmune diseases and it is responsible for most of the deaths occurred to women. Some of the most frequently occurring diseases are type-1 diabetes, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, grave’s disease, and others.
The outbreak of COVID-19 pandemic had a significant impact on the US in vitro diagnostics & laboratory developed tests for autoimmune disease market due to the rising demand for IVD test kits for the detection of SARS-CoV2 virus. The tests are also widely used to diagnose various biological samples at the same time.
Moreover, the fast launch of the diagnostics kit for the diagnosis of COVID-19 is estimated to be a major key driver of the market. For instance, the US Food and Drug Administration (FDA) authorized the emergency use of in vitro diagnostics & laboratory developed test for diagnosis of COVID-19 in February 2020.
Market Trends, Drivers, Restraints, and Opportunities
Rise in awareness regarding the benefits for using in vitro diagnostics & laboratory developed test for autoimmune disease for the disease treatment is projected to boost the market revenue.
Various government policies and initiatives encouraging the adoption of the test and expansion of activities in the field of research, education, patient services, and others are expected to act as a driving factor for the market.
Increase in number of the autoimmune diseases patients globally is a major driving factor of the market.
Development of advanced technology and automation of laboratories facilities coupled with the presence of specialized medical staff such as doctors, nurses, and technician are major factor expected to fuel the market growth.
Continuous research in the field of molecular diagnostics for the early diagnosis of such disorders and treatment is driving the market growth.
Need for various diagnostics test that also result in sluggish turnaround time for results coupled with high cost of the test and certain issues regarding reimbursement are the key restraining factors of the market.
Scope of US In Vitro Diagnostics & Laboratory Developed Test for Autoimmune Disease Market Report
The report on the US in vitro diagnostics & laboratory developed test for autoimmune disease market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
US In Vitro Diagnostics & Laboratory Developed Test for Autoimmune Disease Market - Industry Analysis, Growth, Share, Size, Trends, And Forecast
Applications (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Alopecia Areata, systemic Sclerosis, Lupus Erythematoses, and Others), Technology (Clinical Chemistry, Coagulation, Immunoassays, Microbiology, Hematology, and Molecular Diagnostics)
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Abbott, Omega Diagnostics Group PLC; Beckton Dickinson & Co.; Siemens Healthcare GmbH; SQI Diagnostics; Roche Diagnostics; and Bio-Rad Laboratories, Inc.
US In Vitro Diagnostics & Laboratory Developed Test for Autoimmune Disease Market Segment Insights
Psoriasis segment is expected to register a fast CAGR
Based on applications, the market is divided into rheumatoid arthritis, ankylosing spondylitis, psoriasis, alopecia areata, systemic sclerosis, lupus erythematoses, and others. The rheumatoid arthritis segment held a major share of the market in 2020 and is projected to account for a key market share during the forecast period. The segment expansion can be attributed to rapid development of laboratory for the testing due to rising cases of rheumatoid arthritis. According to the Arthritis Foundation, nearly 1.5 million of people are affected by the disease alone in the US.
However, the psoriasis segment is expected to register a fast CAGR due to wide prevalence of psoriasis, which results in adding a burden on the healthcare-related economy. In addition, several awareness campaigns are being organized by International Federation of Psoriasis Associations, including World Psoriasis Day, to create public awareness about the disease. This is a key factor propelling the market growth.
Molecular diagnostics segment is anticipated to grow at a rapid pace
On the basis of technology, the US in vitro diagnostics & laboratory developed test for autoimmune disease market is segmented into clinical chemistry, coagulation, immunoassays, microbiology, hematology, and molecular diagnostics. The clinical chemistry segment held a key share of the market in 2020 and is expected to constitute a major share in the coming years.
Urine and blood are the most common samples used for clinical chemistry for the diagnosis of autoimmune disorders and autoantibodies are widely used for the diagnosis. However, the molecular diagnostics segment is anticipated to grow at a rapid pace during the projected period owing to the advancement of technology and the rise in demand for NGS technology. The diagnosis of prognosis is widely conducted using next-generation multiplexing tools.
The US in vitro diagnostics & laboratory developed test for autoimmune disease market has been segmented on the basis of
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Alopecia Areata
- systemic Sclerosis
- Lupus Erythematoses
- Clinical Chemistry
- Molecular Diagnostics
Key players competing in the US in vitro diagnostics & laboratory developed test for autoimmune disease market are Abbott, Omega Diagnostics Group PLC; Beckton, Dickinson & Co.; Siemens Healthcare GmbH; SQI Diagnostics; Roche Diagnostics; and Bio-Rad Laboratories, Inc.
These players have adopted business strategies such as launching new products, introducing new technology, merger, partnership, and production capacity expansion to increase their market position and expand their consumer base globally. Some of these players are primarily focusing on the development of technology that can help in the diagnosis of various diseases and the cure for such rare diseases.